In a groundbreaking revelation, the neuro immunoassay market is set to redefine the landscape of diagnostics. Projected to be valued at an astounding US$5,303.1 million by 2033, up from US$2,616.1 million in 2023, this market is experiencing an exceptional 7.3% Compound Annual Growth Rate (CAGR) during the forecast period.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-4293
Key Role of Immunoassays Immunoassays (IAs) have emerged as pivotal tools in various bioanalytical domains, ranging from biopharmaceutical analysis and clinical diagnostics to security, environmental monitoring, and food testing. These chemical tests play a critical role in the detection and quantification of specific substances through immunological reactions.
Neuro Immunoassay: Swift and Precise At the forefront of this revolution is Neuro Immunoassay, a test method that combines swiftness and precision, making it suitable for both on-site and laboratory applications. This innovative approach enables the identification of specific molecules with unparalleled accuracy, opening doors to more effective diagnostics and research in the realm of neurology and beyond.
Unlocking New Possibilities The surge in the neuro immunoassay market reflects the broader transformation taking place in the healthcare industry. With its swift and precise capabilities, neuro immunoassays are set to enhance our understanding of neurologic disorders, accelerate drug development, and improve patient care.
Enhancing Healthcare Ecosystem As the market continues to grow, the healthcare ecosystem is evolving, propelling us into a future where rapid and accurate diagnostics are paramount. The rise of neuro immunoassays is a testament to our commitment to advancing healthcare and addressing complex medical challenges.
Exploring New Horizons With the neuro immunoassay market on the rise, we invite you to stay tuned for further developments, innovations, and breakthroughs. This remarkable growth is not just about numbers; it’s about a brighter, healthier future for all.
Some of the key players in the neuro immunoassay market are: Intrinsic LifeSciences, Danaher Corporation (Beckman Coulter), Becton Dickinson and Company, Akers Biosciences, Inc., Abbott Laboratories, Inc, EDP Biotech Corporation, Hologic (Gen-Probe), Biomérieux, and others.
Recent Development in the Neuro Immunoassay Market:
- In May 2023, Beckman Coulter introduced a new immunoassay analyzer known as DxI 9000 Access. This innovative analyzer has the capability to perform up to 215 tests per hour per square meter (tests/h/m²).
- In March 2023, the release of the Lumipulse G NfL CSF and Lumipulse G NfL Blood tests was officially announced by H.U. Group Holdings Inc. and Fujirebio. The completely automated random-access LUMIPULSE® G immunoassay systems are intended to work with these assays. They utilize CLEIA (chemiluminescent enzyme immunoassay) technology. Neurofilament light (NfL) can potentially be quantitatively measured using the tests in human plasma/serum and cerebral spinal fluid (CSF), respectively.
- In January 2023, the United States FDA granted approval for Leqembi (lecanemab-irmb). The approval was obtained through the Accelerated Approval pathway.. It belongs to a new category of medications that target the fundamental pathophysiology of the Alzheimer’s disease. This approval marks a significant advancement in the ongoing efforts to effectively treat Alzheimer’s disease.
- In September 2022, QIAGEN partnered with Neuron23. Their collaboration aims to develop an assay for detecting biomarkers discovered by Neuron23. This assay is intended to predict the responsiveness of Parkinson’s disease to the LRRK2 inhibitor.
- In July 2022, Labcorp launched a new test. This test offers concrete proof of neuronal damage and neurodegeneration. The Neurofilament Light Chain (NFL) blood test is the first of its kind. It enables medical professionals to spot and confirm neurodegenerative disease symptoms. With this test, physicians can offer a more effective and efficient path to diagnosis and treatment for patients.
- In June 2022, Becton Dickinson and Company which is global leader in medical technology, and a leading private equity firm Frazier Healthcare Partners who focus on healthcare sector – announced an agreement for the former to acquire Parata Systems which is an innovative provider of pharmacy automation solutions for $1.525 billion.
Key Segments:
By Technology:
- Radioimmunoassays (RIA)
- Polymerase Chain Reaction (PCR)
- ELISA
- Western Blot
- Rapid Tests
- ELISPOT
By Product Type:
- Reagents and Kits
- Analysers
By Application:
- Alzheimer’s Disease
- Parkinson’s Disease
- Huntington’s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Spinal Muscular Atrophy (SMA)
By End User:
- Hospitals
- Clinics
- Academic Organizations
- Biopharmaceutical Companies
- Pharmaceutical Companies
- Others
By Region:
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
- Europe
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-4293
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
